Clinical trials: Antipsychotic
Early-onset Schizophrenia
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
In this study,investigators will recruit 100 DSM-Ⅴdefined EOS Han patients, older than 7 years old and onset of illness before 17 years old, and all EOS patients will receive a 8-week systematic olanzepine titration treatment and…
- Trial name
- NCT02435654
- Testing
- olanzapine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Kunming Medical University
Hyponatremia, SIADH
Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study
This study seeks to investigate if hyponatraemia be a direct contributor to death in schizophrenic and bipolar patients, and gauge the potential role of somatic comorbidity and psychotropic polypharmacy, with emphasis on…
- Trial name
- NCT04409626
- Testing
- Plasma sodium level (continuous variables)
- Volunteers
- 31,740 people
- Sponsor
- Zealand University Hospital
Adolescent Depression
Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy
We hypothesize that antipsychotic induced hyperprolactinemia can decrease bone mineral accrual and decrease bone mineral content (BMC) in adolescents on antipsychotic therapy. Specifics Aims 1.
- Trial name
- NCT00399776
- Testing
- Bone Density Test
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Creighton University
Bipolar Disorder
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
- Trial name
- PAMS (NCT00746252)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Bipolar Disorder
Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics
This pilot study hypothesizes that diagnosed and undiagnosed prevalence of diabetes mellitus may differ across antipsychotioc medications in a community mental health center.
- Conditions
- Schizophrenia, Bipolar Disorder, Diabetes Mellitus
- Trial name
- NCT00224276
- Volunteers
- 100 people
- Sponsor
- Yale University
Autism Spectrum Disorder
Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder
Psychotropic medications are the first-line treatment across several diagnostic categories encompassing severe mood disturbances and behavioral problems.
- Trial name
- ACORN-ASD (NCT03865719)
- Testing
- Healthy Habits for Life
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
Dyskinesia, Drug-Induced
Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00837707
- Testing
- aripiprazole
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Mental Disorders
Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children
The proposed study aims to begin the multi-step process of establishing the reliability and validity of hepatic triglyceride content (HTGC) and carotid artery intima-media thickness (IMT) as biomarkers of cardiometablic risk in…
- Trial name
- NCT00894738
- Testing
- Testing (MRS, US, DEXA, blood tests)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Tobacco Dependence, Schizophrenia
The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
Cigarette smoking represents a major health problem for patients suffering from schizophrenia. Compared to the general population, schizophrenic patients are significantly more likely to be addicted to nicotine.
- Trial name
- PSIAARP (NCT00495352)
- Testing
- Hihg-doseNRT, Low-dose NRT, bupropion
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- Yu-Li Hospital
Adverse Drug Event
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population
Introduction: Second Generation Antipsychotics (SGAs) are widely used in the pediatric population. It is currently established that SGAs may induce undesirable metabolic adverse events (AEs) such as weight gain, metabolic changes…
- Trial name
- MEMAS (NCT04395326)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- St. Justine's Hospital
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Child Behavior Disorders
Safer Use of Antipsychotics in Youth
This study tests the effectiveness of an intervention treatment algorithm vs. usual care control in a practical clinical trial. Control arm providers will receive a standard medication alert in the electronic medical record (EMR)…
- Trial name
- SUAY (NCT03448575)
- Testing
- Control - Provider Medication Alert Only, Intervention - Alert + CAP Review AND Enhanced BH Access
- Where
- 4 sites in United States
- Volunteers
- 733 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Hyperprolactinemia, Puberty Disorders
PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
The objectives of this study are: 1. To determine the prevalence and degree of hyperprolactinemia in children and adolescents aged 7-18 years receiving antipsychotic medications 2.
- Conditions
- Hyperprolactinemia, Puberty Disorders, Metabolic Syndrome, Growth Disorders
- Trial name
- PROSA (NCT05033119)
- Where
- 3 sites in Denmark
- Volunteers
- 90 people
- Sponsor
- Ulla Schierup Nielsen
Weight Gain
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount…
- Trial name
- PREVENT (NCT00617240)
- Testing
- metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Adiposity
MR Imaging of Fat Deposition in Adolescents With First Time Antipsychotic Use
This study will focus on a population of antipsychotic (AP) naïve adolescents and young adults and will measure fat accumulation in relation to exposure to atypical antipsychotic medications.
- Trial name
- NCT02744313
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Centre for Addiction and Mental Health
Rhabdomyolysis, Myopathy
Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients
1. Analyze the various causes of breakdown of muscle fibers in hospitalized patients. 2. Analyze the characteristics of these patients in Taiwan (including the drugs history, risk factors and the incidence of complications).
- Conditions
- Rhabdomyolysis, Myopathy, Acute Renal Failure, Neuroleptic Malignant Syndrome
- Trial name
- NCT01022450
- Where
- Taiwan
- Volunteers
- 2,500 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Schizoaffective Disorder
An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
The aim of this study is to evaluate the effectiveness, safety, and tolerability of metformin treatment in children and adolescents suffering from weight gain secondary to use of atypical antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NCT00391261
- Testing
- Metformin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cambridge Health Alliance